These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27367615)

  • 1. Towards antiviral therapies for treating dengue virus infections.
    Kaptein SJ; Neyts J
    Curr Opin Pharmacol; 2016 Oct; 30():1-7. PubMed ID: 27367615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Antiviral Testing for Dengue Virus Infection in Mouse Models and Its Association with Clinical Studies.
    Watanabe S; Low JG; Vasudevan SG
    ACS Infect Dis; 2018 Jul; 4(7):1048-1057. PubMed ID: 29756760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten years of dengue drug discovery: progress and prospects.
    Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
    Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational drugs in early development for treating dengue infection.
    Beesetti H; Khanna N; Swaminathan S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1059-69. PubMed ID: 27322111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in antiviral drug development towards dengue virus.
    Troost B; Smit JM
    Curr Opin Virol; 2020 Aug; 43():9-21. PubMed ID: 32795907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for dengue: a patent review (2010-2014).
    Beesetti H; Khanna N; Swaminathan S
    Expert Opin Ther Pat; 2014 Nov; 24(11):1171-84. PubMed ID: 25283170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue Antiviral Development: A Continuing Journey.
    Low JG; Gatsinga R; Vasudevan SG; Sampath A
    Adv Exp Med Biol; 2018; 1062():319-332. PubMed ID: 29845542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue Virus Evolution under a Host-Targeted Antiviral.
    Plummer E; Buck MD; Sanchez M; Greenbaum JA; Turner J; Grewal R; Klose B; Sampath A; Warfield KL; Peters B; Ramstedt U; Shresta S
    J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients.
    Sung C; Wei Y; Watanabe S; Lee HS; Khoo YM; Fan L; Rathore AP; Chan KW; Choy MM; Kamaraj US; Sessions OM; Aw P; de Sessions PF; Lee B; Connolly JE; Hibberd ML; Vijaykrishna D; Wijaya L; Ooi EE; Low JG; Vasudevan SG
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004851. PubMed ID: 27509020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological intervention for dengue virus infection.
    Lai JH; Lin YL; Hsieh SL
    Biochem Pharmacol; 2017 Apr; 129():14-25. PubMed ID: 28104437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptides as Therapeutic Agents for Dengue Virus.
    Chew MF; Poh KS; Poh CL
    Int J Med Sci; 2017; 14(13):1342-1359. PubMed ID: 29200948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The search for nucleoside/nucleotide analog inhibitors of dengue virus.
    Chen YL; Yokokawa F; Shi PY
    Antiviral Res; 2015 Oct; 122():12-9. PubMed ID: 26241002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dengue virus non-structural 1 protein: risks and benefits.
    Amorim JH; Alves RP; Boscardin SB; Ferreira LC
    Virus Res; 2014 Mar; 181():53-60. PubMed ID: 24434336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for development of Dengue virus inhibitors.
    Noble CG; Chen YL; Dong H; Gu F; Lim SP; Schul W; Wang QY; Shi PY
    Antiviral Res; 2010 Mar; 85(3):450-62. PubMed ID: 20060421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of lanatoside C against dengue virus infection.
    Cheung YY; Chen KC; Chen H; Seng EK; Chu JJ
    Antiviral Res; 2014 Nov; 111():93-9. PubMed ID: 25251726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. True Blood: dengue virus evolution.
    Wash R; Soria CD
    Nat Rev Microbiol; 2015 Nov; 13(11):662. PubMed ID: 26439086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model.
    Rathore AP; Paradkar PN; Watanabe S; Tan KH; Sung C; Connolly JE; Low J; Ooi EE; Vasudevan SG
    Antiviral Res; 2011 Dec; 92(3):453-60. PubMed ID: 22020302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of andrographolide against dengue virus.
    Panraksa P; Ramphan S; Khongwichit S; Smith DR
    Antiviral Res; 2017 Mar; 139():69-78. PubMed ID: 28034742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological characteristics of dengue virus and potential targets for drug design.
    Qi RF; Zhang L; Chi CW
    Acta Biochim Biophys Sin (Shanghai); 2008 Feb; 40(2):91-101. PubMed ID: 18235970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
    Melino S; Paci M
    FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.